Disclosing third-quarter earnings that included $186 million in U.S. sales of Avonex (interferon beta 1-a), Biogen Inc. also said it has settled the longstanding dispute with alpha interferon patent licensee Schering-Plough Corp., gaining a payment of $45 million to $50 million due by the end of the year. (BioWorld Today) Read More
